DYN Q3 2022 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$42M

Net Income

-$41M

EPS (Diluted)

$-0.78

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$44M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$300M

Total Liabilities

$50M

Stockholders' Equity

$250M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$42M	-$43M	+1.1%
Net Income	-$41M	-$43M	+2.8%